- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Acetylcholine provocation testing can help predict major adverse CV and cerebrovascular events
![Acetylcholine provocation testing can help predict major adverse CV and cerebrovascular events Acetylcholine provocation testing can help predict major adverse CV and cerebrovascular events](https://medicaldialogues.in/h-upload/2021/08/14/750x450_158948-heart-2.webp)
A new study conducted by Rocco Antonio Montone and team found that in both ischemia with non-obstructive coronary arteries (INOCA) and myocardial infarction with non-obstructive coronary arteries (MINOCA) patients, the frequency of moderate and temporary problems during acetylcholine (ACh) provocation testing is comparable. The findings of this study were published in EuroIntervention.
For individuals with suspected myocardial ischemia and non-obstructive coronary arteries, intracoronary provocation testing with acetylcholine is essential for the identification of functional coronary abnormalities. The purpose of this study was to evaluate the safety and predictive value of major adverse cardiovascular and cerebrovascular events (MACCE) in patients who presented with myocardial infarction or ischemia with non-obstructive coronary arteries.
For this investigation, INOCA or MINOCA patients who were having intracoronary acetylcholine provocation testing were prospectively included.
The key findings of this study were:
1. There were 317 patients enrolled in all, 174 (54.9%) of whom received INOCA, while 143 (45.1%) received MINOCA. 185 of these individuals (58.4%) responded well to the ACh test.
2. There was no difference between patients who had positive or negative reactions to the ACh testing, nor between INOCA and MINOCA patients, when it came to complications during ACh provocative testing.
3. They were all minor and temporary, and they affected 29 (9.1%) of the patients.
4. Independent risk factors for problems were a history of paroxysmal atrial fibrillation, moderate to severe diastolic dysfunction, and a larger QT dispersion on the baseline ECG. 30 individuals (9.5%) with a median follow-up of 22 months experienced MACCE.
5. A positive ACh test was an independent predictor of MACCE and was associated with a greater frequency of MACCE in patients.
In conclusion, there may be a net therapeutic advantage from doing ACh provocation testing in this clinical environment as it can help identify individuals who are more likely to experience subsequent clinical events.
Reference:
Montone, R. M., Rinaldi, R., Del Buono, M. G., Gurgoglione, F., La Vecchia, G., Russo, M., Caffè, A., Burzotta, F., Leone, A. M., Romagnoli, E., Sanna, T., Pelargonio, G., Trani, C., Lanza, G. A., Niccoli, G., & Crea, F. (2022). Safety and prognostic relevance of acetylcholine testing in patients with stable myocardial ischaemia or myocardial infarction and non-obstructive coronary arteries. In EuroIntervention (Vol. 18, Issue 8, pp. e666–e676). Europa Digital & Publishing. https://doi.org/10.4244/eij-d-21-00971
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: editorial@medicaldialogues.in. Contact no. 011-43720751